Novo Nordisk slashes US cash prices for Wegovy and Ozempic
COPENHAGEN – Danish drugmaker Novo Nordisk said on Monday it has cut U.S. consumer prices for its weight-loss drug Wegovy and diabetes treatment Ozempic, expanding efforts by the company and the Trump administration to improve access to the blockbuster medicines. The company is reducing the monthly cost for most cash-paying patients to $349 from $499….